Evidence map›Paper›PMID 7479741›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1995

The BCL2 major breakpoint region is a sequence- and cell-cycle-specific binding site of the Ku antigen.

P A DiCroce, T G Krontiris

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Detection of BCL2 rearrangements in follicular lymphoma.The American journal of pathology · 2002
    Review
  4. Article
  5. Review
  6. Article
  7. DNA looping by Ku and the DNA-dependent protein kinase.Proceedings of the National Academy of Sciences of the United States of America · 1997
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

P A DiCroceDepartment of Medicine (Hematology/Oncology), Tufts University School of Medicine, Boston, MA, USA.
T G Krontiris
Tufts University · US

Funding

DETERMINANTS OF BCL2 ONCOGENE TRANSLOCATIONR01CA051985 · NCI · TUFTS MEDICAL CENTER · PI KRONTIRIS, THEODORE G · 1991 to 1998
–
NCI NIH HHS CA51985
6 · The paper itself

Abstract

The majority of translocations involving BCL2 are very narrowly targeted to three breakpoint clusters evenly spaced over a 100-bp region of the gene's terminal exon. We have recently shown that the immediate upstream boundary of this major breakpoint region (mbr) is a specific recognition site for single-strand DNA (ssDNA) binding proteins on the sense and antisense strands. The downstream flank of the mbr is a helicase binding site. In this report we demonstrate that the helicase and ssDNA binding proteins show reciprocal changes in binding activity over the cell cycle. The helicase is maximally active in G1 and early S phases; the ssDNA binding proteins are maximally active in late S and G2/M phases. An inhibitor of helicase binding appears in late S and G2/M. Finally, at least one component of the helicase binding complex is the Ku antigen. Thus, a protein with helicase activity implicated in repair of double-strand breaks, variable (diversity) joining recombination, and, potentially, cell-cycle regulation is targeted to the BCL2 mbr.

Indexed as

Antigens, NuclearCell CycleDNA HelicasesProto-OncogenesTranslocation, GeneticBase SequenceBinding SitesCell LineConsensus SequenceDNA-Binding ProteinsDNA, NeoplasmDNA PrimersExonsHL-60 CellsHumansKu AutoantigenAntigens, NuclearDNA-Binding ProteinsDNA HelicasesDNA, NeoplasmDNA PrimersKu AutoantigenNuclear ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Transcription FactorsXRCC5 protein, humanXrcc6 protein, human

Identifiers

PMID7479741
PMCPMC40751
OpenAlexW2016115885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.